These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36198531)

  • 21. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
    Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
    Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
    Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
    Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
    Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
    Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
    Wu X; Wang L; Shen L; He L; Tang K
    J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation.
    Yeshurun M; Pasvolsky O; Shargian L; Yahav D; Ben-Zvi H; Rubinstein M; Sela-Navon M; Wolach O; Raanani P; Rozovski U
    Clin Microbiol Infect; 2022 Feb; 28(2):303.e1-303.e4. PubMed ID: 34715348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Mori Y; Uchida N; Harada T; Katayama Y; Wake A; Iwasaki H; Eto T; Morishige S; Fujisaki T; Ito Y; Kamimura T; Takahashi T; Imamura Y; Tanimoto K; Ishitsuka K; Sugita J; Kawano N; Tanimoto K; Yoshimoto G; Choi I; Hidaka T; Ogawa R; Takamatsu Y; Miyamoto T; Akashi K; Nagafuji K
    Am J Hematol; 2023 Jan; 98(1):102-111. PubMed ID: 36260658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination.
    Pizzano U; Facchin G; Marcon C; Fabris M; Battista ML; Cerno M; Geromin A; Pucillo M; Petruzzellis G; Vianello G; Battaglia G; Peressutti R; Grillone L; Tascini C; Curcio F; Fanin R; Patriarca F
    Transpl Infect Dis; 2023 Apr; 25(2):e14003. PubMed ID: 36748718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
    Barnes E; Goodyear CS; Willicombe M; Gaskell C; Siebert S; I de Silva T; Murray SM; Rea D; Snowden JA; Carroll M; Pirrie S; Bowden SJ; Dunachie SJ; Richter A; Lim Z; Satsangi J; Cook G; Pope A; Hughes A; Harrison M; Lim SH; Miller P; Klenerman P; ; Basu N; Gilmour A; Irwin S; Meacham G; Marjot T; Dimitriadis S; Kelleher P; Prendecki M; Clarke C; Mortimer P; McIntyre S; Selby R; Meardon N; Nguyen D; Tipton T; Longet S; Laidlaw S; Orchard K; Ireland G; ; Thomas D; Kearns P; Kirkham A; McInnes IB;
    Nat Med; 2023 Jul; 29(7):1760-1774. PubMed ID: 37414897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
    Spyridonidis A
    Br J Haematol; 2023 Apr; 201(1):9-10. PubMed ID: 36477621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.
    Sharifi Aliabadi L; Azari M; Taherian MR; Barkhordar M; Abbas SAM; Azari M; Ahmadvand M; Salehi Z; Rouzbahani S; Vaezi M
    Virol J; 2024 May; 21(1):103. PubMed ID: 38702752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients.
    Leclerc M; Redjoul R; Le Bouter A; Beckerich F; Robin C; Parinet V; Pautas C; Menouche D; Bouledroua S; Roy L; Cabanne L; Nait-Sidenas Y; Fourati S; Maury S
    J Hematol Oncol; 2022 Mar; 15(1):27. PubMed ID: 35303906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
    Canti L; Humblet-Baron S; Desombere I; Neumann J; Pannus P; Heyndrickx L; Henry A; Servais S; Willems E; Ehx G; Goriely S; Seidel L; Michiels J; Willems B; Liston A; Ariën KK; Beguin Y; Goossens ME; Marchant A; Baron F
    J Hematol Oncol; 2021 Oct; 14(1):174. PubMed ID: 34689821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of two-dose SARS-CoV-2 vaccination
    Chen CC; Huang YJ; Lai MJ; Lin MH; Lin WC; Lin HY; Lin YC; Huang YT; Lee YF; Tsai MK; Lee CY
    Front Immunol; 2022; 13():951576. PubMed ID: 36189313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals.
    Healy K; Pin E; Chen P; Söderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith CIE; Ljungman P; Valentini D; Blennow O; Österborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Yousef J; Mravinacova S; Cuapio A; Xu X; Akber M; Loré K; Hellström C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren HG; Hober S; Nilsson P; Aleman S; Sällberg Chen M
    Med; 2022 Feb; 3(2):137-153.e3. PubMed ID: 35075450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.